Efficacy of atorvastatin in primary hypercholesterolemia

American Journal of Cardiology

Volumn 79, Issue 9, 1997, Pages 1248-1252

  Nakamura, ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; APOLIPOPROTEINS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PYRROLES; TRIGLYCERIDES;

EID: 8244259180     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00092-1     Document Type: Article

References (7)

1. Bocan TA, Ferguson E, McNally W, Uhlendorf PD, Mueller B, Dehart P, Sliskovic DR, Roth BD, Krause BR, Newton RS. Hepatic and non-hepatic sterol synthesis and tissue distribution following administration of a Liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors. Biochim Biophys Acta, 1992;1123: 133-144.
2. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz L, Lupien PJ, Jones PH, Haber HE, Black DM. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995;15:678-682.
3. Auerbach BJ, Krause BR, Bisgaier CL, Newton RS. Comparative effects of HMG-CoA reductase inhibitors on apoB production in the casein-fed rabbit: atorvastatin versus lovastatin. Atherosclerosis 1995;115:173-180.
4. Fridewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
5. Noma A, Hata Y, Goto Y. Quantitation of serum apolipoprotein A-I, A-II, B, C-II, C-III and E in healthy Japanese by turbidimetric immunoassay: reference values, and age- and sex-related difference. Clin Chim Acta 1991;199:147-158.
6. Hara H, Yokoyama S. Interaction of free apolipoproteins with macrophages. Formation of high density lipoprotein-like lipoprotein and reduction of cellular cholesterol. J Biol Chem 1991;266:3080-3086.
7. Insull W, Black D, Dujovne C, Hosking JD, Hunninghake D, Keilson L, Knopp R, Mckenney J, Stein E, Troendle AJ, Wright JT. Efficacy and safety of once-daily vs. twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia. Arch Intern Med 1994;154:2449-2455.